Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Datopotamab Deruxtecan Generates PFS Benefit in Previously Treated HR+/HER2-Low or HER2– Breast Cancer

September 22nd 2023

Datopotamab deruxtecan elicited a statistically significant and clinically meaningful improvement in progression-free survival compared with chemotherapy in patients with inoperable or metastatic hormone receptor–positive, HER2-low or HER2-negative breast cancer.

Dr Esteva on the Use of CDK4/6 Inhibitors in HR+/HER2– Breast Cancer

September 22nd 2023

Francisco J. Esteva, MD, PhD, discusses the use of CDK4/6 inhibitors in patients with hormone receptor-positive/HER2-negative breast cancer.

European Commission Approves Elacestrant for Pretreated, ESR1+, ER+/HER2– Breast Cancer

September 20th 2023

The European Commission has approved elacestrant for the treatment of postmenopausal women and men with estrogen receptor–positive, HER2-negative, locally advanced, or metastatic breast cancer with an activating ESR1 mutation who have disease progression following at least 1 line of endocrine therapy including a CDK4/6 inhibitor.

Dr Graff on the Impact of Endocrine Therapy Interruption on Conception in Breast Cancer Survivors

September 19th 2023

Stephanie L. Graff, MD, discusses the advantages of interrupting endocrine therapy in premenopausal patients with endocrine-responsive breast cancer who are seeking to conceive, based on findings from the phase 3 POSITIVE trial.

Antibody Drug Conjugates in the Treatment of Endocrine-Resistant HR+/HER2- mBC

September 19th 2023

Key opinion leaders review the use of antibody-drug conjugates (ADCs) in treating HR+/HER2- metastatic breast cancer, and how they counsel patients before starting them on therapy with an ADC.

Optimizing Treatment Strategies in the Evolving HR+/HER2- Breast Cancer Paradigm

September 19th 2023

Over the past 10 years, data from studies including the TAILORx and RxPONDER studies have reshaped treatment standards for patients with hormone receptor–positive, HER2-negative breast cancer.

Treatment Options for Patients with Endocrine-Resistant HR+/HER2- mBC

September 19th 2023

Experts discuss the complexity of defining endocrine resistance in patients with HR+/HER2- metastatic breast cancer and the options for treatment.

Common Toxicities of CDK4/6 Inhibitors in Patients With HR+/HER2- Metastatic Breast Cancer

September 19th 2023

The panel explains how treatment experience with CDK4/6 inhibitors varies for patients with HR+/HER- breast cancer, and which agents are best tolerated.

Considerations for Use of CDK4/6 Inhibitors in HR+/HER2- Metastatic Breast Cancer

September 19th 2023

Dr Naomi Dempsey explains how she decides on an appropriate CDK4/6 inhibitor for patients receiving first-line treatment for metastatic HR+/HER- breast cancer.

Dr West on Adjuvant Endocrine Therapy Plus a CDK4/6 Inhibitor in Early-Stage Breast Cancer

September 18th 2023

Malinda West, MD, MS, discusses the use of adjuvant endocrine therapy in combination with CDK4/6 inhibitors in the treatment of patients with early-stage HER2-negative breast cancer.

Continued Research Underscores the Need to Explore New Approaches Across the Breast Cancer Armamentarium

September 15th 2023

Stephanie L. Graff, MD, expands on treatment options available for patients with premenopausal breast cancer who are trying to conceive, highlighting the POSITIVE trial in women with endocrine-responsive breast cancer.

Dr Phadke on the Benefit of Sacituzumab Govitecan in HR+/HER2– Breast Cancer

September 14th 2023

Sneha Phadke, DO, MPH, discusses the benefit associated with treatment consisting of the antibody drug conjugates sacituzumab govitecan in hormone receptor-positive/HER2-negative breast cancer.

Dr Sharifi on the Importance of ctDNA Testing in Breast Cancer

September 14th 2023

Marina Sharifi, MD, PhD, discusses the benefit of utilizing personalized and targeted therapy approaches in the treatment of patients with breast cancer.

Frontline CDK4/6 Inhibitors in HR+/HER2- Metastatic Breast Cancer

September 13th 2023

Naomi Dempsey, MD, reviews data on the use of CDK4/6 inhibitors for the frontline treatment of metastatic HR+/HER- breast cancer.

Monitoring and Treating Lymphedema in Patients With HR+/HER- Breast Cancer

September 13th 2023

Nadia Nocera Zachariah, MD, explains why early detection and monitoring of lymphedema is crucial in patients with HR+/HER- breast cancer, with technologies like prophylactic compression sleeves and nighttime compression systems showing promise in reducing negative impact on quality of life.

Dr Phadke on Sequencing ADCs in HR+/HER2– Breast Cancer

September 12th 2023

Sneha Phadke, DO, MPH, discusses sequencing treatment with antibody drug conjugates in hormone receptor-positive/HER2-negative breast cancer, as well as questions remaining within this space.

Case Presentation: A 72-Year-Old Woman With HR+/HER2- mBC

September 12th 2023

Virginia Kaklamani, MD, presents the case of a 47-year-old premenopausal woman diagnosed with HR+/HER2- metastatic breast cancer for discussion.

Overview of HR+/HER2- Metastatic Breast Cancer (mBC)

September 12th 2023

Virginia Kaklamani, MD, and Elizabeth Diaz, PA-C, offer an overview of HR+/HER2- metastatic breast cancer and detail the standard-of-care first-line therapy options.

Dr Hamilton on the Benefit Derived From Adjuvant Ribociclib in HR+/HER2– Breast Cancer

September 8th 2023

Erika P. Hamilton, MD, discusses the benefit seen with adjuvant ribociclib in patients with hormone receptor-positive,HER2-negative breast cancer.

Updates in Adjuvant Therapy for HR+/HER- Breast Cancer From ASCO 2023: The NATALEE Trial

September 6th 2023

Dr Naomi Dempsey shares the study design, primary outcome data, and the 3-year invasive disease-free survival follow-up data from the NATALEE trial in HR+/HER2- breast cancer presented at ASCO 2023.